Expanding Direct-To-Patient Options, BMS/Pfizer Add Eliquis To Cost Plus Drugs Portal

Bristol Myers Squibb and Pfizer have added their anticoagulant drug Eliquis to the Cost Plus Drugs portal, expanding direct-to-patient options for cash-paying customers. This move follows an earlier decision by the companies to sell discounted Eliquis directly. The article highlights a growing trend among drugmakers to offer lower prices for medicines outside traditional channels.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin